RSS Feeds
Fibrinogen and Cardiovascular Risk
- Edzard Ernst, MD; and
- Karl Ludwig Resch, MD
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
Include no more than 300 words of text, three authors, and five references
Type with double-spacing
Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
IN RESPONSE:
Several points raised in this letter are relevant. The pharmacologic alteration of fibrinogen seems a grossly under-researched area. Many drugs influence the alteration but often it is difficult to determine if it results from the drug's effect on a given disorder or is a direct effect of the drug itself.
That fibrinogen levels increase in intermittent claudication has been observed repeatedly. Recently, Lowe and coworkers [1] reported epidemiologic data showing that the increase is independently associated with peripheral arterial narrowing. Thus, a prognostic relevance of fibrinogen in peripheral arterial occlusive disease comes as little surprise, particularly when considering that it is of prognostic value in atherosclerosis of other major vascular trees, as shown in our meta-analysis [2].
Research of fibrinogen as a cardiovascular risk factor is booming internationally; no doubt we will soon learn more about it.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
Include no more than 300 words of text, three authors, and five references
Type with double-spacing
Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
- Copyright 2004 by the American College of Physicians
